The efficacy of tucatinib-based therapeutic approaches for HER2-positive breast cancer

Overexpression of human epidermal growth factor receptor 2 (HER2) occurs in approximately 15–20% of breast cancer cases. HER2 is a member of the epidermal growth factor receptor (EGFR) family with tyrosinase kinase activity, and its overexpression is linked to poor prognosis and shorter progression-...

Descripción completa

Detalles Bibliográficos
Autores principales: Sirhan, Zaid, Thyagarajan, Anita, Sahu, Ravi P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9277867/
https://www.ncbi.nlm.nih.gov/pubmed/35820970
http://dx.doi.org/10.1186/s40779-022-00401-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9277867/
https://www.ncbi.nlm.nih.gov/pubmed/35820970
http://dx.doi.org/10.1186/s40779-022-00401-3

Ejemplares similares